Table 4.
Multiple linear regression analysis for ln [TRACP-5b/iPTH]
| Variable | Model 1 | Model 2 | Model 3 | Model 4 |
|---|---|---|---|---|
| Age, years | 0.006 [−0.008, 0.021] | 0.004 [−0.011, 0.019] | 0.007 [− 0.009, 0.023] | |
| Female sex | 0.204 [−0.086, 0.494] | 0.186 [−0.107, 0.478] | 0.190 [− 0.103, 0.484] | |
| BMI, kg/m2 | −0.019 [− 0.057, 0.019] | −0.020 [− 0.057, 0.018] | ||
| Alb, g/dL | 0.219 [−0.321, 0.759] | |||
| CaSR agonist use | ||||
| None | (base) | (base) | (base) | (base) |
| Cinacalcet/ Evocalcet | −0.329* [− 0.642, − 0.015] | −0.313 [− 0.630, 0.004] | −0.296 [− 0.623, 0.030] | −0.284 [− 0.612, 0.045] |
| Etelcalcetide (i.v.) | −1.029** [−1.716, − 0.342] | −0.932** [− 1.629, − 0.236] | −0.940** [− 1.639, − 0.240] | −0.886* [− 1.599, − 0.173] |
| VDRA use | ||||
| None | (base) | (base) | (base) | (base) |
| Alfacalcidol/ Falecalcitriol | −0.349 [− 0.926, 0.236] | −0.344 [− 0.927, 0.239] | −0.299 [− 0.888, 0.290] | −0.305 [− 0.895, 0.285] |
| Calcitriol (i.v.) | − 0.770** [− 1.340, − 0.200] | −0.815** [− 1.389, − 0.240] | −0.772* [− 1.353, − 0.191] | −0.791** [− 1.374, − 0.207] |
| Maxacalcitol (i.v.) | −0.749* [− 1.385, − 0.113] | −0.791* [− 1.434, − 0.148] | −0.810* [− 1.456, − 0.164] | −0.831* [− 1.481, − 0.182] |
| cCa, mg/dL | 0.171 [− 0.057, 0.399] | 0.117 [− 0.057, 0.398] | 0.177 [− 0.051, 0.406] | 0.209 [− 0.033, 0.451] |
| P, mg/dL | −0.123 [− 0.264, 0.017] | −0.113 [− 0.257, 0.029] | −0.095 [− 0.245, 0.054] | −0.097 [− 0.247, 0.053] |
| ln [1, 25(OH)2D] | − 0.156 [− 0.470, 0.158] | −0.207 [− 0.528, 0.113] | −0.207 [− 0.529, 0.115] | −0.213 [− 0.535, 0.110] |
Abbreviations: Alb Serum albumin, BMI Body mass index, CaSR Calcium-sensing receptor, cCa Corrected Ca, iPTH Intact parathyroid hormone, i.v. Intravenous, ln Natural logarithm, P Phosphorus, TRACP-5b Tartrate-resistant acid phosphatase-5b, VDRA Vitamin D receptor activator
Values are expressed as the median [interquartile range (IQR)] or as frequencies and percentages [n (%)]. *P < 0.05, **P < 0.01
Coefficient [95% CI]
Model 1: CaSR agonist use (None, Cinacalcet/Evocalcet, Etelcalcetide), VDRA use (None, Alfacalcidol/ Falecalcitriol, Calcitriol, Maxacalcitol), cCa, P, ln [1, 25(OH)2D]
Model 2: CaSR agonist use (None, Cinacalcet/Evocalcet, Etelcalcetide), VDRA use (None, Alfacalcidol/ Falecalcitriol, Calcitriol, Maxacalcitol), cCa, P, ln [1, 25(OH)2D], Age, Sex
Model 3: CaSR agonist use (None, Cinacalcet/Evocalcet, Etelcalcetide), VDRA use (None, Alfacalcidol/ Falecalcitriol, Calcitriol, Maxacalcitol), cCa, P, ln [1, 25(OH)2D], Age, Sex, BMI
Model 4: CaSR agonist use (None, Cinacalcet/Evocalcet, Etelcalcetide), VDRA use (None, Alfacalcidol/ Falecalcitriol, Calcitriol, Maxacalcitol), cCa, P, ln [1, 25(OH)2D], Age, Sex, BMI, Alb